Image
Insights
In-depth articles and expert analysis from pharmaceutical leaders, exploring advances in life sciences, drug development and the trends shaping healthcare innovation.
Image
Can AI and Machine Learning in Sterile Manufacturing Improve Quality?
Image
Optimising Clinical Trial Data Collection for Better Decisions
Image
What Drives Pharmaceutical R&D Success? New Benchmarking Reveals Why Some Drug Pipelines Outperform Others
Biomedical R&D
Image
Can Large Language Models Solve More Rare Disease Genomes?
AI & Machine Learning
Image
Can Large Language Models Solve More Rare Disease Genomes?
AI & Machine Learning
Image
Modular Pharma Factories: The Next Step for Continuous Manufacturing?
Continuous Manufacturing
Explore All Insights
Browse our complete library of expert articles and analysis. Explore content across science, policy and life sciences innovation.
What Drives Pharmaceutical R&D Success? New Benchmarking Reveals Why Some Drug Pipelines Outperform Others
Explore new benchmarking research on pharmaceutical R&D success rates, revealing why some drug pipelines consistently achieve higher approval rates than others.
Success for Non-Animal Testing of Preclinical Toxicity?
Can non-animal testing methods be used in preclinical drug discovery? Here is what the evidence is for their accuracy and limits assessing preclinical toxicity.
Great Drug Discovery Starts with Great Scientists
Learn how drug discovery scientists are evolving alongside AI, computational biology, and multidisciplinary research to accelerate therapeutic innovation.
GLP-1 Drug Discovery Success Transformed Pharmaceutical R&D
From gut hormones to global therapeutics, GLP-1 drug discovery transformed obesity treatment through peptide engineering and incretin biology translation.
Can Deep Learning Survive the Precision Medicine Paradox?
As precision medicine narrows patient cohorts to rare‑disease scales, deep learning models face a paradox of data scarcity and overfitting that threatens the future of clinical AI.
Genomic Governance Ensures Equity at the Core of Drug Discovery
Discover why genomic equity is essential for reliable AI-driven drug discovery, precision medicine, and building more representative pharmaceutical innovation.
Optimising Preclinical Pharmacology for Oncology NMEs
Over 90% of oncology NMEs that succeed in animal studies fail in clinical trials. This analysis examines how to optimise preclinical pharmacology models to improve translational success.
FDA 2026 Draft Guidance on Alternatives to Animal Testing
The FDA's March 2026 draft guidance on alternatives to animal testing marks a pivotal shift in preclinical drug development. Here's what pharma R&D teams need to know.
Reimagine AI-driven Drug Discovery with Pharma Superintelligence
Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.
Phenotypic Drug Discovery: Beyond the Target
Phenotypic drug discovery is reshaping how pharma finds first-in-class drugs. This analysis covers the methods, AI integration, and strategic decisions R&D leaders face in 2026.
Cell Therapy for Solid Tumours: Current Challenges and New Advances
Cell therapy for solid tumours faces unique biological barriers. This analysis unpacks the engineering strategies pharma leaders must understand for R&D success in 2026.
Why Precision Alone Isn't Enough in Oncology Drug Discovery
Precision alone isn’t enough in oncology drug discovery. See why execution, biomarkers, and trial design determine scalable success in precision medicine.
